-

Shareholder Alert: Robbins LLP is Investigating Activision Blizzard, Inc. (ATVI) for Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Activision Blizzard, Inc. (NASDAQ: ATVI) to determine whether certain Activision officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Activision develops and publishes interactive entertainment content and services in the Americas and abroad.

Activision Blizzard, Inc. (ATVI) Accused of Sexual Harassment Against Female Employees

After a two-year investigation, the California Dept. of Fair Employment and Housing filed a lawsuit against the Company alleging a "pervasive frat boy workplace culture." The agency found that the Company discriminated against female employees in terms of conditions of employment, including compensation, assignment, promotion, and termination and consistently failed to take steps to prevent discrimination, harassment, and retaliation. In response, nearly 1,000 current and former Activision employees have signed a letter calling the Company's responses to the lawsuit "abhorrent and insulting," and dozens of current and former employees have come out on social media to share their own allegations of discrimination. Additionally, several gaming outlets have halted coverage of any games released by the Company.

Activision Blizzard, Inc. (ATVI) shareholders have legal options against the Company's officers and directors. If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Robbins LLP is a nationally recognized leader in shareholder rights law. To receive free alerts about corporate executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ATVI

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Reminds Intuit Inc. Investors With Significant Losses of the Opportunity to Lead the the Securities Fraud Class Action Against INTU

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Intuit Inc. (NASDAQ: INTU ) securities between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”).The lawsuit alleges that Intuit misled investors about the sustainability and growth of its business, including its TurboTax business, and failed to disclose increasing competitive and pricing pressures affecti...

Investor Alert: Robbins LLP Informs Investors of the Wise Group plc Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom